Conmed (CNMD) Cash & Equivalents (2010 - 2026)

Conmed has reported Cash & Equivalents for 17 years, with the latest figure at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 1.28% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $35.0 million (down 1.28% YoY), and the FY2025 full-year result was $40.8 million, up 66.88% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $35.0 million, down from $40.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $53.2 million in Q2 2022, with the low at $24.3 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $32.9 million across 5 years, with a median of $33.4 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 47.61% — and 2025, when it soared 66.88%.
• Conmed's Cash & Equivalents stood at $28.9 million in 2022, then fell by 16.05% to $24.3 million in 2023, then advanced by 0.67% to $24.5 million in 2024, then soared by 66.88% to $40.8 million in 2025, then slipped by 14.18% to $35.0 million in 2026.
• The last three Cash & Equivalents figures came in at $35.0 million (Q1 2026), $40.8 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.